

Dynamic list Drugs and indications to be considered by the London Cancer New Drugs Group (LCNDG) for the Cancer Drugs Fund and Work Plan.

The London Cancer Drugs Fund review process:

The Prioritisation process informs the recommendations made to Commissioners for the funding of new cancer medicines and new indications for existing medicines, in London.

The medicines and indications highlighted by the Prioritisation process inform the workplan of the London Cancer New Drugs group and then the list which constitutes the Cancer Drugs Fund list for London.

It is important that the reviews by the London Cancer New Drugs Group (LCNDG) take place before recommendations for funding are made.

Cancer Drugs Fund List

This Cancer Drugs Fund list of medicines and Indications is in two parts.

1. The standard list of medicines and indications which for which a CDF application form is required. Application is made to the relevant Cancer Network Management team using drug/indication specific application forms.
2. Near off-label indication applications will be reviewed by the London Cancer Drugs Fund Panel, prior to approval. Application is made to the relevant Cancer Network Management Team who will co-ordinate the panel review. A generic Near off-label form is used for such applications.

The Dynamic list and LCNDG workplan

This provides the list of medicines and indications, their current NICE, LCNDG and CDF status and a schedule for when the LCNDG will discuss.

The list will be reviewed at each of the bi-monthly LCNDG meetings and changes made as appropriate, as medicines and indications are added to and removed from the CDF list.

When medicines and indications are removed from the CDF list, patients who have had their treatment approved for funding via the CDF prior to the removal date, will continue to be funded via the CDF and the three monthly audit forms must still be submitted to the London Audit Office

Please note:

The number of reviews which need to be completed by the LCNDG has increased with the implementation of the CDF, which has increased the workload of the Medicines Information departments which complete the reviews.

Therefore a scheduled time plan for these LCNDG reviews has been made available, which will be reviewed regularly.

It is important that clinicians and pharmaceutical companies recognise that the process is not instantaneous and that the reviews constitute the quality assurance for decisions made by the group.

London Cancer New Drugs Group

Drug	Indication	NICE Status Updated 25-11-11	Licence status	ICDF Status 24-03-11 / date added to list	2011/12 Pan-London prioritisation colour assigned	LCNDG Status	Date to add to CDF	Date to remove from CDF list	Reason for removal from CDF list	Comments
------	------------	------------------------------	----------------	---	---	--------------	--------------------	------------------------------	----------------------------------	----------

Dynamic list of drugs and indications to be considered for the Cancer Drugs Fund or commissioning via the pan-London Cancer Drug Prioritisation process and work plan.

Abiraterone	Metastatic advanced castrate resistant prostate cancer, after previous chemotherapy including a taxane	In progress Due date May 2012	Licensed	Not on ICDF list	NA	LCNDG review discussed September 2011, approved for CDF list	28/09/2011			
Bendamustine	Previously untreated stage II multiple myeloma with progressive diseases or stage III multiple myeloma. In patients >65yrs, not eligible for transplant and with clinical neuropathy	Not on NICE timetable	off label	Not on ICDF list	Amber	Review date to be confirmed				
Bevacizumab	First line in Metastatic breast cancer patients with either triple negative tumours OR prior taxane therapy	Declined on clinical and cost effectiveness grounds TA 214 Feb 2011	Licensed	Not on ICDF list	Red	LCNDG review to be prepared for discussion at Jan12 meeting				
Bevacizumab	2nd Line Colorectal Cancer	TA212 negative Dec 10	Licensed	on list from 01-10-10	Amber	NICE declined on cost effectiveness grounds only, additional LCNDG review not indicated	01/04/2011			
Bortezomib	2nd or subsequent relapse in Refractory Mantle cell Lymphoma, in patients not fit for transplant	Will not be considered	off-label	on list from 08-02-2011	Green	17.05.11 - LCNDG to review when licensed in this indication therefore remain on CDF	01/04/2011			
Bortezomib	Second and subsequent line Multiple Myeloma	1st relapse NICE approved TA129	Licensed	on list from 01-10-10	N/A	NICE declined on cost effectiveness grounds only, additional LCNDG review not indicated	01/04/2011			
Cabazitaxel	2nd line treatment of hormone-refractory prostate cancer following docetaxel-based therapy	In progress Date due Feb 2012	Licensed	Not on ICDF list	Amber	LCNDG review discussed July 2011, approved for CDF list	27/07/2011			

London Cancer New Drugs Group

Drug	Indication	NICE Status Updated 25-11-11	Licence status	ICDF Status 24-03-11 / date added to list	2011/12 Pan-London prioritisation colour assigned	LCNDG Status	Date to add to CDF	Date to remove from CDF list	Reason for removal from CDF list	Comments
Caelyx (in combination with Carboplatin)	2nd line platinum sensitive Ovarian Ca	NICE approved for partially platinum-sensitive, platinum-resistant or platinum-refractory ovarian May 05	Licensed	on list from 08-02-2011	Blue	LCNDG reviewed July 2011 – pan-London prioritisation score validated, remain on CDF list	01/04/2011			
Caelyx (pegylated liposomal doxorubicin)	1st or 2nd line Angiosarcoma, especially cutaneous	Will not be considered	off label	on list from 08-02-2011	Blue	LCNDG reviewed Sept 11, to remain on CDF list	01/04/2011			
Caelyx (pegylated liposomal doxorubicin)	1st line Primary Sarcoma of Heart and great vessels	Will not be considered	off label	on list from 08-02-2011	Blue	LCNDG reviewed Sept 11, to remain on CDF list	01/04/2011			
Caelyx (pegylated liposomal doxorubicin)	1st or 2nd line Sarcoma patients with cardiac impairment needing an anthracycline	Will not be considered	off label	on list from 08-02-2011	Blue	LCNDG reviewed Sept 11, to remain on CDF list	01/04/2011			
Caelyx (pegylated liposomal doxorubicin)	2nd line Fibromatosis (desmoid tumour)	Will not be considered	off label	on list from 08-02-2011	Blue	LCNDG reviewed Sept 11, to remain on CDF list	01/04/2011			
Cetuximab	Squamous Cell Carcinoma of the Head & Neck 1st line + platinum	Declined on cost effectiveness grounds TA172 June 09	Licensed	on list from 01-10-10	Amber	NICE declined on cost effectiveness grounds only, additional LCNDG review not indicated	01/04/2011			
Cetuximab	First line treatment of KRAS Wild type metastatic colorectal cancer	TA176 positive *	Licensed	on list from 01-10-10	N/A	NICE declined whole cohort on cost effectiveness grounds only, additional LCNDG review not indicated	01/04/2011			*for neoadjuvant cohort only where live mets may become operable
Cetuximab	continuation of treatment in patients receiving cetuximab in NICE TA 176 but have failed to become operable at 16 weeks but who have not progressed	Declined on cost effectiveness grounds TA176 Aug 2009	Licensed	on list from 01-10-10	Amber	Sub-group of indication above. NICE declined on cost effectiveness grounds only, additional LCNDG review not indicated	01/04/2011			

London Cancer New Drugs Group

Drug	Indication	NICE Status Updated 25-11-11	Licence status	ICDF Status 24-03-11 / date added to list	2011/12 Pan-London prioritisation colour assigned	LCNDG Status	Date to add to CDF	Date to remove from CDF list	Reason for removal from CDF list	Comments
Cetuximab +/- irinotecan	3rd line Refractory k-ras wild type metastatic colorectal	Whole population declined on cost effectiveness grounds Jan 07, KRAS wild type not considered	Licensed	on list from 01-10-10	N/A	NICE declined on cost effectiveness grounds only, additional LCNDG review not indicated	01/04/2011			
Decitabine (Dacogen)	Myelodysplastic syndrome High risk IPSS Score in patients suitable for BSC only	Not considered for this indication	Licence due 2012	Not on ICDF list	Green	Review to be undertaken when licensed				
Degarelix (vs average Goserelin/ Leuporelin/ Triptorelin)	Newly diagnosed advanced prostate cancer for subgroup with areas of critical metastases including those with established or incipient spinal cord compression are or at risk of urinary retention using standard LHRH & those where there is need to avoid pro-thrombotic risk of steroidal anti-androgens	Rejected for consideration by NICE Nov 07	Licensed	on list from 08-02-2011	Blue	LCNDG reviewed July 2011 – pan-London prioritisation score validated. To remain on CDF list	01/04/2011			
Eribulin mesylate	Locally advanced metastatic breast cancer which has progressed after at least 2 chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane, unless not suitable	FAD negative Nov 2011	Licensed	NA	Red	LCNDG review discussed September 2011, approved for CDF list	28/09/2011			New data published since prioritisation assessment for 2011-12
Everolimus	advanced renal cell carcinoma in patients whose disease has progressed on or after treatment with VEGF-targeted therapy	Declined, on cost effectiveness grounds, TA219	Licensed	on list from 01-10-10	Amber	NICE TAG -ve on cost effectiveness grounds only, additional LCNDG review not indicated	01/04/2011			

London Cancer New Drugs Group

Drug	Indication	NICE Status Updated 25-11-11	Licence status	ICDF Status 24-03-11 / date added to list	2011/12 Pan-London prioritisation colour assigned	LCNDG Status	Date to add to CDF	Date to remove from CDF list	Reason for removal from CDF list	Comments
Everolimus	Unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.	Not on NICE timetable	Licensed	Not on ICDF list	Red	LCNDG review discussed September 2011, approved for CDF list	28/09/2011			
Fulvestrant	3rd or 4th line hormone therapy for locally advanced or metastatic Breast cancer	FAD negative Nov11	Licensed	on list from 01-10-10	Red	LCNDG reviewed July 2011, agreed to remain on CDF list	01/04/2011			
gemcitabine	adjuvant pancreas	Will not be considered	off-label	Not on ICDF list	Amber	Review date to be confirmed				
Gemcitabine and Cisplatin	1st line advanced Biliary tract	Will not be considered	off-label	Not on ICDF list	Amber	Review date to be confirmed				
ipilimumab	Previously treated unresectable Stage III or IV melanoma	In progress Date due Feb 2012	Licensed	Not on ICDF list	Amber	LCNDG review discussed September 2011, approved for CDF list	28/09/2011			
Irinotecan and Temozolamide	3rd line Relapsed Ewings sarcoma	Will not be considered	off label	Not on ICDF list	Amber	Review date to be confirmed				
Lapatinib + Aromatase Inhibitor	Hormone sensitive adv or met Breast cancer	FAD negative July 11	Licensed	Not on ICDF list	Amber	LCNDG review to be prepared for discussion at Jan12 meeting				
Lapatinib + Capecitabine	In combination with capecitabine for the treatment of advanced or metastatic HER2 +ve breast cancer who have had prior therapy that includes trastuzumab	NICE suspended review Oct 10	Licensed	on list from 01-10-10	Red	LCNDG reviewed Nov11, agreed to remain on CDF list	01/04/2011			
Lenalidomide	First relapse Multiple Myeloma	Declined June 09 on cost effectiveness grounds	Licensed	on list from 01-10-10	Green	NICE declined on cost effectiveness grounds only, additional LCNDG review not indicated	01/04/2011			
Mitotane	Adjuvant Adrenocortical Carcinoma	Will not be considered	Off-label	on list from 08-02-2011	Green	LCNDG reviewed May 2011 pan-London prioritisation score validated. Currently unlicensed in this indication therefore	01/04/2011			

London Cancer New Drugs Group

Drug	Indication	NICE Status Updated 25-11-11	Licence status	ICDF Status 24-03-11 / date added to list	2011/12 Pan-London prioritisation colour assigned	LCNDG Status	Date to add to CDF	Date to remove from CDF list	Reason for removal from CDF list	Comments
						remain on CDF				
Pazopanib	2nd line Advanced / metastatic Renal Cell Carcinoma, post treatment with cytokines	Suspended from NICE work program Apr 10	Licensed	Not on ICDF list	Amber	LCNDG to consider Review date to be confirmed				
Pemetrexed	Second line Non Small Cell Lung Cancer Non-Squamous	TA124 negative*	Licensed	on list from 01-10-10	N/A	Review not completed	01/04/2011			*Non-squamous histology, not considered by NICE at this time.
Rituximab +/- chemo	1st line waldenstrom's macroglobulinaemia	Will not be considered	Near off-label	Not on ICDF list	Amber	Review date to be confirmed	01/04/2011			
Rituximab +chemo	2nd or 3rd line relapsed refractory Mantle Cell Lymphoma	Will not be considered	Near off-label	on list from 08-02-2011	Green	LCNDG reviewed May 2011 pan-London prioritisation score validated. However currently unlicensed in this indication therefore remain on CDF	01/04/2011			
Rituximab weekly x 4	1st line HIV associated Castleman	Will not be considered	Near off-label	on list from 08-02-2011	Light green	LCNDG reviewed September 2011 – pan-London prioritisation score validated, to remain on CDF list	01/04/2011			
Sorafenib	1st line Advanced Hepatocellular Carcinoma	Declined May 10 on cost effectiveness grounds	Licensed	on list from 01-10-10	Amber	NICE declined on cost effectiveness grounds only, additional LCNDG review not indicated	01/04/2011			
Sorafenib	Advanced Hepatocellular Carcinoma with underlying liver cirrhosis due to Hepatitis C	Declined May 10 on cost effectiveness grounds Sub-population not considered	Licensed	on list from 01-10-10	Amber	Sub-group of indication above. NICE declined on cost effectiveness grounds only, additional LCNDG review not indicated	01/04/2011			

London Cancer New Drugs Group

Drug	Indication	NICE Status Updated 25-11-11	Licence status	ICDF Status 24-03-11 / date added to list	2011/12 Pan-London prioritisation colour assigned	LCNDG Status	Date to add to CDF	Date to remove from CDF list	Reason for removal from CDF list	Comments
Sunitinib	unresectable or metastatic pancreatic neuroendocrine tumours (excluding poorly differentiated tumours) with disease progression	Not on NICE timetable	Licensed	Not on ICDF list	Red	LCNDG identified new data and agreed addition to CDF list – May 2011	31/05/2011			
Topotecan	Recurrent carcinoma of the cervix in patients with prior exposure to cisplatin > 6 months prior to relapse	TA183 positive for cisplatin naïve only	Licensed	on list from 01-10-10	N/A	Review not completed	01/04/2011			
Yttrium 90 resin microspheres radio-embolisation	3rd line liver predominant metastatic colorectal chemotherapy refractory cancer	Interventional Procedure Guidance positive IPG 401, July 2011	Medical device BSI approved CE marked	Not on ICDF list	Amber	LCNDG reviewed Nov 11, agreed to be added to CDF list	30/11/2011			

London Cancer New Drugs Group

Drug	Indication	NICE Status Updated 25-11-11	Licence status	ICDF Status 24-03-11 / date added to list	2011/12 Pan-London prioritisation colour assigned	LCNDG Status	Date to add to CDF	Date to remove from CDF list	Reason for removal from CDF list	Comments
Drugs and Indications which have been removed from the London Cancer New Drugs Group and Cancer Drugs Fund workplan										
Alemtuzumab	Fludarabine refractory Chronic Lymphocytic Leukaemia (with or without 17p deletion) relapsed within 6 months of fludarabine containing regimen	Will not be considered	Licensed	on list from 08-02-2011	Green	LCNDG reviewed May 2011 - pan-London prioritisation score validated.	01/04/2011	28/06/2011	Approved by LCNDG, for funding via standard commissioning pathways in London	Notification forms only required for patients starting treatment after 28 th June 2011 See note on page 1 relating to ongoing funding and audit requirements for patients funded via CDF prior to the removal date.
Azacitidine	Intermediate 2 and high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder, acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia	TA218 +ve 23-03-11	Licensed	on list from 01-10-10	N/A	declined on cost effectiveness grounds	01/04/2011	28/06/2011	3 months post NICE approval, for routine commissioning	See note on page 1 relating to ongoing funding and audit requirements for patients funded via CDF prior to the removal date.
Bendamustine	First line Chronic Lymphocytic Leukaemia in patients unsuitable for fludarabine based treatment	TA216 Positive Mar 11	Licensed	on list from 01-10-10	Amber	NICE approved LCNDG review not indicated	01/04/2011	28/06/2011	3 months post NICE approval, for routine commissioning	See note on page 1 relating to ongoing funding and audit requirements for patients funded via CDF prior to the removal date.
Bortezomib	1st line Multiple Myeloma in patients presenting with renal failure	FAD Positive June 2011 (All 1st line)	Licensed in the first line setting	on list from 08-02-2011	Blue	LCNDG reviewed May 2011 – pan-London prioritisation score validated.	01/04/2011	28/06/2011	Approved by LCNDG, for funding via standard commissioning pathways in London	Notification forms only required from 28/06/2011 See note on page 1 relating to ongoing funding and audit requirements for patients funded via CDF prior to the removal date.
Bortezomib+ alkylating agent and corticosteroid	1st line Multiple Myeloma for patients unsuitable for transplant and unable to tolerate or has contra-indications to thalidomide.	FAD Positive June 2011	Licensed	on list from 08-02-2011	Green	LCNDG reviewed May 2011 pan-London prioritisation score validated.	01/04/2011	28/06/2011	Approved by LCNDG, for funding via standard commissioning pathways in London	Notification forms only required from 28/06/2011 See note on page 1 relating to ongoing funding and audit requirements for patients funded via CDF prior to the removal date.

London Cancer New Drugs Group

Drug	Indication	NICE Status Updated 25-11-11	Licence status	ICDF Status 24-03-11 / date added to list	2011/12 Pan-London prioritisation colour assigned	LCNDG Status	Date to add to CDF	Date to remove from CDF list	Reason for removal from CDF list	Comments
Erlotinib	Monotherapy for the maintenance treatment of non-small cell lung cancer in patient who have achieved stable disease on Platinum based 1st line therapy	TA227 negative July-2011	Licensed	on list from 01-10-10	Red	Review not completed	01/04/2011	27/07/2011	NICE concerns on clinical and cost effectiveness grounds	Patients currently receiving erlotinib monotherapy for maintenance treatment of locally advanced or metastatic non-small-cell lung cancer who have stable disease after platinum-based first-line chemotherapy should have the option to continue treatment until they and their clinician consider it appropriate to stop.
Imatinib	1st line Philadelphia positive Acute Lymphoblastic Leukaemia	Will not be considered	Licensed	on list from 08-02-2011	Light green	LCNDG reviewed May 2011 – pan-London prioritisation score validated.	01/04/2011	28/06/2011	Approved by LCNDG, for funding via standard commissioning pathways in London	Notification forms only required from 28/06/2011 See note on page 1 relating to ongoing funding and audit requirements for patients funded via CDF prior to the removal date.
Irinotecan + raltitrexed	2nd line Advanced pancreas	Will not be considered	off-label	Not on ICDF list	Amber	LCNDG reviewed Nov 11, not approved for addition to CDF list				
Mifamurtide + chemo	newly diagnosed resectable osteosarcoma	FAD negative Oct 10 on cost effectiveness grounds	licensed	Not on ICDF list	Amber	LCNDG reviewed July 11, not for addition to CDF list on clinical and cost effectiveness grounds	NA	NA	NA	
Rituximab	Maintenance treatment following response to first line chemotherapy for follicular lymphoma	TA226 positive June 2011	Licensed	Not on ICDF list	Amber	LCNDG reviewed July 11	NA	NA	NA	NICE approved June 2011
Temsirolimus	1st line non-clear cell advanced Renal Cell Carcinoma	Reviewed by NICE, TA178 Specific sub-considered small and imprecisely defined	Licensed	Not on ICDF list	Amber	LCNDG reviewed September 11, not for addition to CDF list on clinical and cost effectiveness grounds	NA	NA	NA	
Temsirolimus	Relapsed Refractory Mantle cell Lymphoma	Data not submitted to NICE by company	Licensed	Not on ICDF list	Amber	Not eligible for CDF as data not submitted to NICE				

London Cancer New Drugs Group

Drug	Indication	NICE Status Updated 25-11-11	Licence status	ICDF Status 24-03-11 / date added to list	2011/12 Pan-London prioritisation colour assigned	LCNDG Status	Date to add to CDF	Date to remove from CDF list	Reason for removal from CDF list	Comments
Trabectedin + Lip Dox	2nd line Relapsed Ovarian cancer, partially platinum sensitive, (platinum free interval 6-12 months)	TA222 negative May 2011 on clinical and cost effectiveness grounds	Licensed	Not on ICDF list	Amber	LCNDG reviewed July 11, not for addition to CDF list on clinical and cost effectiveness grounds	NA	NA	NA	
Trastuzumab + Capecitabine	Beyond Progression	Declined in Clinical Guideline Feb 09-not clear if clinical or cost effectiveness grounds	Off-label	Not on ICDF list	Amber	LCNDG reviewed Nov11, agreed not to add to CDF list				